Literature DB >> 29434894

Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells.

Zhenyu Hou1, Yunfeng Cui1, Huizhi Xing2, Xiaoyan Mu2.   

Abstract

The present study investigated whether poly(ADP-ribose) polymerase (PARP) has an effect on p53-regulated pancreatic cancer. The results of the present study demonstrated that the expression of PARP affects proliferation and apoptosis of pancreatic cancer cells. Olaparib was used to suppress the expression level of PARP-1 in PanC-1 cells. Decreased expression of PARP-1 suppressed cell proliferation and induced apoptosis of PanC-1 cells when compared with controls. Furthermore, decreased expression of PARP-1 resulted in decreased levels of pro-caspase-3 expression, increased caspase-3 activity, suppressed B-cell lymphoma 2 (Bcl-2) protein expression and increased p53 protein expression in PanC-1 cells. Subsequently, ataxia telangiectasia mutated (ATM) activity was inhibited alongside down-expression of PARP-1 resulting in significantly decreased cellular viability of PanC-1 cells, increased p53 protein expression, decreased expression of pro-caspase-3, increased caspase-3 activity and suppressed Bcl-2 protein expression, when compared with PARP-1 suppression alone. Overall, the in vitro data confirmed that down-expression of PARP-1 suppressed cell proliferation and induced apoptosis of pancreatic cancer via ATM-deficient p53 signaling pathway.

Entities:  

Keywords:  ataxia telangiectasia mutated; p53; pancreatic cancer; poly(ADP-ribose) polymerase

Year:  2017        PMID: 29434894      PMCID: PMC5774434          DOI: 10.3892/ol.2017.7500

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

Review 1.  The Bcl-2 family: structures, interactions and targets for drug discovery.

Authors:  Marc Kvansakul; Mark G Hinds
Journal:  Apoptosis       Date:  2015-02       Impact factor: 4.677

Review 2.  Prognostic value of Caspase-3 expression in cancers of digestive tract: a meta-analysis and systematic review.

Authors:  Hao Chen; Xia Yang; Zhenbo Feng; Ruixue Tang; Fanghui Ren; Kanglai Wei; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Determination-of apoptosis and cell cycle modulators (p16, p21, p27, p53, BCL-2, Bax, BCL-xL, and cyclin D1) in thyroid follicular carcinoma, follicular adenoma, and adenomatous nodules via a tissue microarray method.

Authors:  Peyker Temiz; Gizem Akkaş; Nalan Neşe; Fazilet Uğur Duman; Cansu Karakaş; Yamaç Erhan
Journal:  Turk J Med Sci       Date:  2015       Impact factor: 0.973

4.  BCL2 and related prosurvival proteins require BAK1 and BAX to affect autophagy.

Authors:  Lisa M Lindqvist; David L Vaux
Journal:  Autophagy       Date:  2014-06-27       Impact factor: 16.016

5.  APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.

Authors:  Christophe Deben; Filip Lardon; An Wouters; Ken Op de Beeck; Jolien Van den Bossche; Julie Jacobs; Nele Van Der Steen; Marc Peeters; Christian Rolfo; Vanessa Deschoolmeester; Patrick Pauwels
Journal:  Cancer Lett       Date:  2016-03-11       Impact factor: 8.679

6.  Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo.

Authors:  Yilong Li; Yongwei Wang; Le Li; Rui Kong; Shangha Pan; Liang Ji; Huan Liu; Hua Chen; Bei Sun
Journal:  Tumour Biol       Date:  2015-12-16

7.  Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy.

Authors:  R Hill; M Rabb; P A Madureira; D Clements; S A Gujar; D M Waisman; C A Giacomantonio; P W K Lee
Journal:  Cell Death Dis       Date:  2013-09-05       Impact factor: 8.469

8.  A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer.

Authors:  Nobuaki Suzuki; Shoichi Hazama; Tomio Ueno; Hiroto Matsui; Yoshitaro Shindo; Michihisa Iida; Kiyoshi Yoshimura; Shigefumi Yoshino; Kazuyoshi Takeda; Masaaki Oka
Journal:  J Immunother       Date:  2014-01       Impact factor: 4.456

9.  Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.

Authors:  Gaurab Chakrabarti; Zachary R Moore; Xiuquan Luo; Mariya Ilcheva; Aktar Ali; Mahesh Padanad; Yunyun Zhou; Yang Xie; Sandeep Burma; Pier P Scaglioni; Lewis C Cantley; Ralph J DeBerardinis; Alec C Kimmelman; Costas A Lyssiotis; David A Boothman
Journal:  Cancer Metab       Date:  2015-10-12

10.  Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.

Authors:  Ines Lohse; Ramya Kumareswaran; Pinjiang Cao; Bethany Pitcher; Steven Gallinger; Robert G Bristow; David W Hedley
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

View more
  2 in total

1.  Electrochemically Reduced Water Delays Mammary Tumors Growth in Mice and Inhibits Breast Cancer Cells Survival In Vitro.

Authors:  Giovanni Vanni Frajese; Monica Benvenuto; Rosanna Mattera; Saverio Giampaoli; Elena Ambrosin; Roberta Bernardini; Maria Gabriella Giganti; Loredana Albonici; Ivan Dus; Vittorio Manzari; Andrea Modesti; Maurizio Mattei; Roberto Bei
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-26       Impact factor: 2.629

2.  Complementary effects of Orthosiphon stamineus standardized ethanolic extract and rosmarinic acid in combination with gemcitabine on pancreatic cancer.

Authors:  Ashwaq H S Yehya; Muhammad Asif; Amin M S Abdul Majid; Chern E Oon
Journal:  Biomed J       Date:  2020-05-28       Impact factor: 4.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.